

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

VOLUNTARY ANNOUNCEMENT

INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 496,000 SHARES, WITH ACCUMULATED PURCHASE TOTALING 14,210,500 SHARES

This announcement is made by CStone Pharmaceuticals (the “Company”, together with its subsidiaries, collectively referred to as the “Group” or “CStone”) on a voluntary basis to inform its shareholders and potential investors in relation to the increase in shareholding in the Company (the “Shares”) by Dr. Jianxin Yang (“Dr. Yang”), the chief executive officer (the “CEO”), president of research and development and an executive director of the Company.

.....

The Company was informed by Dr. Yang that he had purchased an aggregate of 496,000 Shares in the open market with his personal funds from 17 to 22 September 2026 (the “Share Purchases”), for a total consideration of more than HK\$2.7 million.

The board of directors of the Company (the “Board”) is of the view that the Share Purchases fully demonstrate Dr. Yang's long-term commitment to the Company and his strong confidence in the future business prospects of the Company. Since assuming the role of CEO in August 2022, Dr. Yang has acquired an aggregate of 14,210,500 Shares in the open market. Immediately following the Share Purchases, Dr. Yang is interested in an aggregate of Shares representing approximately 5.31% of the total issued share capital of the Company as at the date of this announcement.

The latest clinical data of the Company's core asset, CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody), will be disclosed in two rapid oral presentations at the European Society for Medical Oncology (ESMO) Congress in October 2026. Dr. Yang expressed his strong confidence in the Company's long-term investment value and core competitive strengths. Dr. Yang does not rule out the possibility of further increasing his shareholding in the Company as and when appropriate.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched four innovative drugs and secured approvals for 21 new drug applications covering nine indications. The Company's pipeline comprises 13 innovative drug candidates, including potential first-in-class or best-in-class antibody-drug conjugates (ADCs) and mono-/multi-specific antibodies across oncology, immunology and inflammation. CStone has an experienced management team with comprehensive capabilities spanning the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By Order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Suzhou, the People's Republic of China, September 24, 2026

As at the date of this announcement, the Board comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III and Mr. Edward Hu as non-executive directors, and Mr. Kenneth Howard Jarrett, Ms. Fang Xie and Ms. Catherine Yen as independent non-executive directors.